Browsing Tag
CD19
5 posts
Can parallel CAR-T targeting finally solve relapse in multiple myeloma
Can dual-targeting CAR-T solve relapse in multiple myeloma? Explore how Tempest Therapeutics, Inc. is positioning TPST-2003 for next-gen impact.
A one-time lupus reset? Why CTA313 is forcing competitors to rethink strategy
Can CTA313 disrupt lupus markets with one-time remission? Explore how Imviva Biotech is reshaping autoimmune competition.
Is TPST-2003’s early efficacy enough to disrupt the current CAR-T landscape in multiple myeloma
Can TPST-2003 disrupt CAR-T therapy in multiple myeloma? Explore what Tempest Therapeutics, Inc.’s strategy means for investors and the industry.
Is Vivacta Bio’s GT801 the next frontier in CAR-T therapy? Early human data reveal scalable, chemo-free promise
Vivacta Bio’s GT801 shows early promise as a repeat-dose in vivo CAR-T therapy for lymphoma. Find out how this could reshape immunotherapy delivery.
AbbVie to acquire Capstan Therapeutics for $2.1bn to expand in vivo CAR-T platform for autoimmune therapy
AbbVie will acquire Capstan Therapeutics for $2.1B, gaining in vivo CAR-T platform and lead asset CPTX2309 in autoimmune therapy. Read full acquisition details.